Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
FDA confirms Class I device recall | Nuclear cardiology enters new era | Health disparities in cardio-oncology | CKM syndrome
Tuesday, October 21, 2025
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

FDA confirms Class I recall for Johnson & Johnson devices due to durability concerns

The issue, first reported in September, was linked to five patient injuries. Devices not being actively used should be returned to Johnson & Johnson MedTech for updates.

READ MORE >
Johnson & Johnson MedTech Automated Impella Controller
Share on Twitter Share on Facebook Share on Linkedin

FDA confirms Class I recall for Johnson & Johnson devices due to durability concerns

Share on Twitter Share on Facebook Share on Linkedin
Johnson & Johnson MedTech Automated Impella Controller
The issue, first reported in September, was linked to five patient injuries. Devices not being actively used should be returned to Johnson & Johnson MedTech for updates.
READ MORE >

Nuclear cardiology expands beyond perfusion imaging as it enters a new era

Beyond amyloidosis, nuclear cardiology is also increasingly used to image inflammation and infection in the myocardium, especially in diseases such as cardiac sarcoidosis and myocarditis.

READ MORE >
Nuclear cardiology is entering a new era—one that goes well beyond the traditional focus on myocardial perfusion imaging. According to Marcelo Di Carli, MD, editor-in-chief of the Journal of Nuclear Cardiology and chief of the Division of Nuclear Medicine at Brigham and Women’s Hospital, the field is rapidly expanding into diagnosing and monitoring complex cardiac diseases such as amyloidosis, sarcoidosis, myocarditis, and cardiac infections.
Share on Twitter Share on Facebook Share on Linkedin

Nuclear cardiology expands beyond perfusion imaging as it enters a new era

Share on Twitter Share on Facebook Share on Linkedin
Nuclear cardiology is entering a new era—one that goes well beyond the traditional focus on myocardial perfusion imaging. According to Marcelo Di Carli, MD, editor-in-chief of the Journal of Nuclear Cardiology and chief of the Division of Nuclear Medicine at Brigham and Women’s Hospital, the field is rapidly expanding into diagnosing and monitoring complex cardiac diseases such as amyloidosis, sarcoidosis, myocarditis, and cardiac infections.
Beyond amyloidosis, nuclear cardiology is also increasingly used to image inflammation and infection in the myocardium, especially in diseases such as cardiac sarcoidosis and myocarditis.
READ MORE >

How clinicians can combat health disparities in cardio-oncology

Researchers, for example, could improve disparities by performing their tests on more diverse groups of patients. Daniel Addison, MD, shared his perspective with Cardiovascular Business. 

READ MORE >
Daniel Addison, MD, Director of Translational Research in the Cardiology Division and Associate Director for Survivorship and Outcomes Research in the Harold C. Simmons Comprehensive Cancer Center. He also holds the Audre and Bernard Rapport Endowed Chair in Cardiovascular Research, UT Southwestern Medical Center. explains the health disparities and inequities involved in cardio-oncology.
Share on Twitter Share on Facebook Share on Linkedin

How clinicians can combat health disparities in cardio-oncology

Share on Twitter Share on Facebook Share on Linkedin
Daniel Addison, MD, Director of Translational Research in the Cardiology Division and Associate Director for Survivorship and Outcomes Research in the Harold C. Simmons Comprehensive Cancer Center. He also holds the Audre and Bernard Rapport Endowed Chair in Cardiovascular Research, UT Southwestern Medical Center. explains the health disparities and inequities involved in cardio-oncology.
Researchers, for example, could improve disparities by performing their tests on more diverse groups of patients. Daniel Addison, MD, shared his perspective with Cardiovascular Business. 
READ MORE >

Most adults know nothing about CKM syndrome—but it impacts nearly everyone

Nearly 90% of adults are believed to already have at least one risk factor of CKM syndrome. The American Heart Association hopes patient education and physician collaborations can help increase awareness about this dangerous condition.

READ MORE >
old woman or doctor shaking hands with patient
Share on Twitter Share on Facebook Share on Linkedin

Most adults know nothing about CKM syndrome—but it impacts nearly everyone

Share on Twitter Share on Facebook Share on Linkedin
old woman or doctor shaking hands with patient
Nearly 90% of adults are believed to already have at least one risk factor of CKM syndrome. The American Heart Association hopes patient education and physician collaborations can help increase awareness about this dangerous condition.
READ MORE >

Featured Articles

FDA approves oral semaglutide for reducing cardiovascular risks in adults with type 2 diabetes

Rybelsus from Novo Nordisk is officially the first oral GLP-1 drug approved for this indication. The FDA's decision was based on the SOUL trial, which included data from more than 9,000 patients with type 2 diabetes.

READ MORE >
approval regulations checkmark doctor
Share on Twitter Share on Facebook Share on Linkedin

FDA approves oral semaglutide for reducing cardiovascular risks in adults with type 2 diabetes

Share on Twitter Share on Facebook Share on Linkedin
approval regulations checkmark doctor
Rybelsus from Novo Nordisk is officially the first oral GLP-1 drug approved for this indication. The FDA's decision was based on the SOUL trial, which included data from more than 9,000 patients with type 2 diabetes.
READ MORE >

PET holds promise for carotid plaque assessments

PET has already gained significant momentum in recent years. Now, researchers are pointing to another possible use for the popular imaging modality: assessing carotid artery atherosclerosis.

READ MORE >
Positron emission tomography (PET) nuclear imaging has seen rapid expansion in cardiology and oncology due to its improve accuracy over SPECT and its ability to expand into new areas of cardiovascular imaging. A new review in the American Heart Association journal Stroke outlines another possible use of PET to assess carotid artery atherosclerosis for stroke prevention. Figure courtesy Stroke, https://www.ahajournals.org/doi/10.1161/STROKEAHA.125.050399
Share on Twitter Share on Facebook Share on Linkedin

PET holds promise for carotid plaque assessments

Share on Twitter Share on Facebook Share on Linkedin
Positron emission tomography (PET) nuclear imaging has seen rapid expansion in cardiology and oncology due to its improve accuracy over SPECT and its ability to expand into new areas of cardiovascular imaging. A new review in the American Heart Association journal Stroke outlines another possible use of PET to assess carotid artery atherosclerosis for stroke prevention. Figure courtesy Stroke, https://www.ahajournals.org/doi/10.1161/STROKEAHA.125.050399
PET has already gained significant momentum in recent years. Now, researchers are pointing to another possible use for the popular imaging modality: assessing carotid artery atherosclerosis.
READ MORE >

Hospital in Mexico earns first heart failure certification of its kind

A facility outside the United States has received the American Heart Association's Comprehensive Heart Failure Center Certification for the first time.

READ MORE >
Hospital staff walking through a medical facility, intentionally blurred to look artistic
Share on Twitter Share on Facebook Share on Linkedin

Hospital in Mexico earns first heart failure certification of its kind

Share on Twitter Share on Facebook Share on Linkedin
Hospital staff walking through a medical facility, intentionally blurred to look artistic
A facility outside the United States has received the American Heart Association's Comprehensive Heart Failure Center Certification for the first time.
READ MORE >

New-onset AFib is common after CABG—but typically not persistent or symptomatic

The study's authors questioned if these patients should even be given oral anticoagulation as currently recommended.

READ MORE >
heart data research doctor cardiologist AI
Share on Twitter Share on Facebook Share on Linkedin

New-onset AFib is common after CABG—but typically not persistent or symptomatic

Share on Twitter Share on Facebook Share on Linkedin
heart data research doctor cardiologist AI
The study's authors questioned if these patients should even be given oral anticoagulation as currently recommended.
READ MORE >

Hypertrophic Cardiomyopathy Association supports study of potential treatment for nonbstructive HCM

No medications are currently approved for the treatment of nonobstructive hypertrophic cardiomyopathy. Could a new drug from Imbria Pharmaceuticals be the first?

READ MORE >
Imbria Pharmaceuticals announced a partnership with the Hypertrophic Cardiomyopathy Association (HCMA) to help expedite patient recruitment for its ongoing FORTITUDE-HCM study looking at the first drug to treat symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM). The debilitating disease currently has no approved treatments.
Share on Twitter Share on Facebook Share on Linkedin

Hypertrophic Cardiomyopathy Association supports study of potential treatment for nonbstructive HCM

Share on Twitter Share on Facebook Share on Linkedin
Imbria Pharmaceuticals announced a partnership with the Hypertrophic Cardiomyopathy Association (HCMA) to help expedite patient recruitment for its ongoing FORTITUDE-HCM study looking at the first drug to treat symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM). The debilitating disease currently has no approved treatments.
No medications are currently approved for the treatment of nonobstructive hypertrophic cardiomyopathy. Could a new drug from Imbria Pharmaceuticals be the first?
READ MORE >

In Case You Missed It

Cardiologist dies after choking on flight—family’s lawsuit points to alleged negligence

According to the lawsuit, the doctor followed a strict vegetarian diet and choked after he was served meat. The family also claims the airline delayed care by waiting too long to perform an emergency landing.

READ MORE >
healthcare AI and aviation
Share on Twitter Share on Facebook Share on Linkedin

Cardiologist dies after choking on flight—family’s lawsuit points to alleged negligence

Share on Twitter Share on Facebook Share on Linkedin
healthcare AI and aviation
According to the lawsuit, the doctor followed a strict vegetarian diet and choked after he was served meat. The family also claims the airline delayed care by waiting too long to perform an emergency landing.
READ MORE >

FDA clears new AI model for MAC detection in routine imaging results

The advanced algorithm was designed to detect and evaluate mitral annular calcification on routine, non-gated CT scans. It is now available as part of Carebricks, a generative AI platform from Bunkerhill Health. 

READ MORE >
robot reviewing heart data
Share on Twitter Share on Facebook Share on Linkedin

FDA clears new AI model for MAC detection in routine imaging results

Share on Twitter Share on Facebook Share on Linkedin
robot reviewing heart data
The advanced algorithm was designed to detect and evaluate mitral annular calcification on routine, non-gated CT scans. It is now available as part of Carebricks, a generative AI platform from Bunkerhill Health. 
READ MORE >

SCAI highlights the benefits of ICE-guided structural heart interventions

ICE is gaining momentum as a helpful imaging option during structural heart interventions, according to a new SCAI position statement. TEE and TTE remain incredibly important, but there are times when ICE can provide the guidance necessary.

READ MORE >
SCAI ICE position statement
Share on Twitter Share on Facebook Share on Linkedin

SCAI highlights the benefits of ICE-guided structural heart interventions

Share on Twitter Share on Facebook Share on Linkedin
SCAI ICE position statement
ICE is gaining momentum as a helpful imaging option during structural heart interventions, according to a new SCAI position statement. TEE and TTE remain incredibly important, but there are times when ICE can provide the guidance necessary.
READ MORE >

In Other News

$30M settlement reached in data breach affecting 2.4M patients

The ransomware attack on Integris Health, a nonprofit health system in Oklahoma, happened in late 2023. Victims of the breach said they were extorted by hackers directly.

READ MORE >
Ransomware Cyberattack Data Breach
Share on Twitter Share on Facebook Share on Linkedin

$30M settlement reached in data breach affecting 2.4M patients

Share on Twitter Share on Facebook Share on Linkedin
Ransomware Cyberattack Data Breach
The ransomware attack on Integris Health, a nonprofit health system in Oklahoma, happened in late 2023. Victims of the breach said they were extorted by hackers directly.
READ MORE >

Combined AI chatbot, telehealth app earns $25M investment

Physician-founded Counsel Health said it will use the funds to hire more doctors as it expands the userbase for its AI, which allows patients to ask questions and get answers from a real doctor.

READ MORE >
Chatbot
Share on Twitter Share on Facebook Share on Linkedin

Combined AI chatbot, telehealth app earns $25M investment

Share on Twitter Share on Facebook Share on Linkedin
Chatbot
Physician-founded Counsel Health said it will use the funds to hire more doctors as it expands the userbase for its AI, which allows patients to ask questions and get answers from a real doctor.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Medtech giant makes big move | The world’s top hospitals for heart surgery | New CPT codes | PET vs. SPECT | TAVR tech recalled
AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme
Trimed Popup